News

GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...
India's anti-obesity drug market is valued at Rs 3,000-3,500 crore and is projected to grow nearly eightfold to Rs 25,000 ...
Previous studies have suggested the drugs may slash the risk of illnesses like dementia and stroke, with an international ...
Metabolic hypogonadism, a condition marked by low testosterone levels and frequently seen in obese individuals, contributes to worsening metabolic health and an increased risk of type 2 diabetes.
Once scorned as a cosmetic lifestyle disfigurement, obesity today is recognised as a chronic and progressive disease. From the altered metabolic deran.